Crystalline solids of a MetAP-2 inhibitor and methods of making and using same
US-9371312-B2 · Jun 21, 2016 · US
Crystalline solids of a metAP-2 inhibitor and methods of making and using same
US9827221B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827221-B2 |
| Application number | US-201615145403-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 3, 2016 |
| Priority date | Nov 9, 2010 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base, wherein the composition is a suspension of the crystalline form in a pharmaceutically acceptable carrier, wherein the crystalline form is characterized by a powder X-ray diffraction pattern having a characteristic peak in degrees 2θ at about 13.3, 17.4, and 19.9. 2. The pharmaceutical composition of claim 1 , wherein the crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base, is characterized by a powder X-ray diffraction pattern having characteristic peaks in degrees 2θ at about 7.1, 13.3, 16.3, 17.4, 18.6, 19.4, and 19.9. 3. The pharmaceutical composition of claim 2 , wherein the crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base, is characterized by a powder X-ray diffraction pattern having characteristic peaks in degrees 2θ at 5.2, 7.1, 10.4, 13.3, 14.2, 16.3, 17.4, 18.6, 19.4, and 19.9. 4. The pharmaceutical composition of claim 1 , wherein the crystalline form of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol, free base, is characterized by the powder X-ray diffraction pattern shown in FIG. 1 . 5. The pharmaceutical composition of claim 1 , wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation. 6. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is an aqueous carrier. 7. A method of treating obesity in a patient in need thereof, comprising subcutaneously administering to the patient an effective amount of the pharmaceutical composition of claim 1 .
Assignees
Inventors
Classifications
by esterified hydroxyl radicals · CPC title
- A61K31/336Primary
having three-membered rings, e.g. oxirane, fumagillin · CPC title
Anorexiants; Antiobesity agents · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
- C07D407/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9827221B2 cover?
- The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof.
- Who is the assignee on this patent?
- Zafgen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).